Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (601-610 of 993) with videos related to

Pageof 100
Sort By:
Current Urology|January 30, 2023
Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registriesRocco Simone Flammia, Benedikt Hoeh, Francesco Chierigo, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
Central European Journal of Urology|November 16, 2022
Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancerRocco Simone Flammia, Francesco Chierigo, Christoph Würnschimmel, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
European Urology|June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
The Prostate|May 31, 2021
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patternsChristoph Würnschimmel, Mike Wenzel, Francesco Chierigo, et al.
The Prostate|July 2, 2026
Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United StatesLeonardo Quarta, Maximilian Filzmayer, Michele Petix, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 16, 2014
Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experienceCôme Tholomier, Marc Bienz, Pierre-Alain Hueber, et al.
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
World Journal of Urology|January 27, 2022
Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patientsGabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, et al.
Pageof 100

Showing results (601-610 of 993) with videos related to

Sort By:
Pageof 100
Current Urology|January 30, 2023
Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registriesRocco Simone Flammia, Benedikt Hoeh, Francesco Chierigo, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
Central European Journal of Urology|November 16, 2022
Sex-related differences in non-urothelial variant histology, non-muscle invasive bladder cancerRocco Simone Flammia, Francesco Chierigo, Christoph Würnschimmel, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
European Urology|June 24, 2022
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1Fred Saad, Johann de Bono, Philippe Barthélémy, et al.
The Prostate|May 31, 2021
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patternsChristoph Würnschimmel, Mike Wenzel, Francesco Chierigo, et al.
The Prostate|July 2, 2026
Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United StatesLeonardo Quarta, Maximilian Filzmayer, Michele Petix, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 16, 2014
Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experienceCôme Tholomier, Marc Bienz, Pierre-Alain Hueber, et al.
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
World Journal of Urology|January 27, 2022
Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patientsGabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, et al.
Pageof 100